Latest Breaking News On - Consortium for enhanced sepsis outcomes - Page 1 : comparemela.com

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced new non-dilutive external funding, additional to the previously announced U.S. Government funding, which now covers the entirety of the RHB-107 (upamostat) arm of the ACESO PROTECT adaptive platform trial for early COVID-19 outpatient treatment. This additional funding amounts to approximately $4.8M directed towards evaluation of RHB-107 in the PROTECT study.

United kingdomSouth africaUnited statesMacau generalHong kongCoted ivoireIvory coastRedhill biopharmaAdi frishRedhill biopharma ltdNuclear countermeasures programDepartment of defenseGermany heidelberg pharmaceuticalsDepartment of the navyConsortium for enhanced sepsis outcomesExchange commission